Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer - A substudy of the neoadjuvant GeparQuinto trial

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Issa Nummer, Yasmin ^a   Darb Esfahani, Silvia ^b   Loibl, Sibylle ^a   Kunz, Georg ^c   Nekljudova, Valentina ^a   Schrader, Iris ^d   Sinn, Bruno Valentin ^b   Ulmer, Hans Ullrich ^e   Kronenwett, Ralf ^f   Just, Marianne ^g   Kühn, Thorsten ^h   Diebold, Kurt ⁱ   Untch, Michael ^j   Holms, Frank ^k   Blohmer, Jens Uwe ^l   Habeck, Jörg Olaf ^m   Dietel, Manfred ^b   Overkamp, Friedrich ⁿ   Krabisch, Petra ^o   Von Minckwitz, Gunter ^a,p   Denkert, Carsten ^b   more..

^a German Breast Group   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

^d Henriettenstiftung   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^f Sividon Diagnostics GmbH   (Germany)

^g Onkologische Schwerpunktpraxis Bielefeld   (Germany)

^h KLINIKUM ESSLINGEN   (Germany)

ⁱ Gemeinschaftspraxis für Pathologie Hamm   (Germany)

^j HELIOS KLINIKUM BERLIN BUCH   (Germany)

^k Abteilung Allgemeine und Viszeralchirurgie   (Germany)

^l MARTIN LUTHER KRANKENHAUS   (Germany)

^m Zentrum für Histopathologie Chemnitz   (Germany)

ⁿ Oncologianova GmbH   (Germany)

^o KLINIKUM CHEMNITZ   (Germany)

^p UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG RESPONSE; HER2 NEGATIVE BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84891590308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079775     Document Type: Article

References (50)

1. Estevez LG, Gradishar WJ (2004) Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10: 3249-3261. 10.1158/1078-0432.CCR-03-0133 [doi];10/10/3249 [pii].
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, et al. (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940-1949. 24/12/1940 [pii];10.1200/JCO.2005.02.6187 [doi].
3. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466.
4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685.
5. Houghton AN, Guevara-Patino JA (2004) Immune recognition of self in immunity against cancer. J Clin Invest 114: 468-471. 10.1172/JCI22685 [doi].
6. Ichim CV (2005) Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med 3: 8. 1479-5876-3-8 [pii];10.1186/1479-5876-3-8 [doi].
7. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2: 293-299.10.1038/86297 [doi].
8. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998. 10.1038/ni1102-991 [doi];ni1102-991 [pii].
9. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50. S0065-2776(06)90001- 7 [pii];10.1016/S0065-2776(06)90001-7 [doi].
10. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213. 10.1056/NEJMoa020177 [doi];348/3/203 [pii].
11. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, et al. (2004) Immune response against dying tumor cells. Adv Immunol 84: 131-179. 10.1016/S0065-2776(04)84004-5 [doi];S0065277604840045 [pii].
12. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666. 353/25/2654 [pii];10.1056/NEJMoa051424 [doi].
13. Denardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212. bcr1746 [pii];10.1186/ bcr1746 [doi].
14. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, et al. (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3: 817-819.
15. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, et al. (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A: 859-864.
16. Denkert C, Loibl S, Noske A, Roller M, Muller BM, et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113. JCO.2009.23.7370 [pii];10.1200/JCO.2009.23.7370 [doi].
17. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, et al. (2008) Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26: 1024-1031. 906934442 [pii];10.1080/07357900802098165 [doi].
18. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, et al. (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277. JCO.2005.02.0818 [pii];10.1200/JCO.2005.02.0818 [doi].
19. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, et al. (2011) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 10.1007/ s10549-011-1554-7 [doi].
20. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, et al. (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26: 778-785. 26/5/778 [pii];10.1200/JCO.2007.15.0235 [doi].
21. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, et al. (2009) Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 4: e6982. 10.1371/journal.pone.0006982 [doi].
22. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648. 10.1007/s00262-006-0225-8 [doi].
23. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, et al. (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14: 2413-2420. 14/8/2413 [pii];10.1158/1078-0432.CCR-07- 4491 [doi].
24. Carson WE, III, Shapiro CL, Crespin TR, Thornton LM, Andersen BL (2004) Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10: 3401-3409. 10.1158/1078-0432.CCR-1016-03 [doi];10/10/3401 [pii].
25. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, et al. (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676-2685. 23/12/2676 [pii];10.1200/JCO.2005.05.078 [doi].
26. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, et al. (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100: 542-551. djn085 [pii];10.1093/jnci/ djn085 [doi].
27. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57: 1579-1587. 10.1007/s00262-008-0505-6 [doi].
28. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543. 0509182102 [pii];10.1073/pnas.0509182102[doi].
29. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11: R15. bcr2234 [pii];10.1186/bcr2234 [doi].
30. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275-280. 6602934 [pii];10.1038/sj.bjc.6602934 [doi].
31. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955. JCO.2010.30.5037 [pii];10.1200/JCO.2010.30.5037 [doi].
32. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8: 151-160. nrclinonc.2010.223 [pii];10.1038/nrclinonc.2010.223 [doi].
33. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28: 4531-4538. JCO.2009.27.2146 [pii];10.1200/JCO.2009.27.2146 [doi].
34. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102. onc2009416 [pii];10.1038/onc.2009.416 [doi].
35. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
36. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009. 0008-5472.CAN-08-2360 [pii];10.1158/0008-5472.CAN-08-2360 [doi].
37. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, et al. (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127: 99-108. 10.1007/s10549-010-0987-8 [doi].
38. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, et al. (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27: 1746-1752. JCO.2008.17.9036 [pii];10.1200/JCO.2008.17.9036 [doi].
39. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380. 24/34/5373 [pii];10.1200/JCO.2006.05.9584 [doi].
40. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, et al. (2001) Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 61: 7889-7899.
41. Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52: 715-738. 10.1007/s00262-003- 0409-4 [doi].
42. Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, et al. (1999) Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer Lett 139: 33-41. S0304-3835(98)00379-6 [pii].
43. Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977-4982. 185/9/4977 [pii];10.4049/jimmunol.1001323 [doi].
44. Rodriguez-Pinto D (2005) B cells as antigen presenting cells. Cell Immunol 238: 67-75. S0008-8749(06)00039-6 [pii];10.1016/j.cellimm.2006.02.005 [doi].
45. Denardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29: 309-316. 10.1007/s10555-010-9223-6 [doi].
46. Punt CJ, Barbuto JA, Zhang H, Grimes WJ, Hatch KD, et al. (1994) Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 38: 225-232.
47. Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 98: 12659-12664. 10.1073/pnas.171460798 [doi];171460798 [pii].
48. Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169: 2701-2711.
49. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, et al. (2011) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 10.1007/s10549-011-1620-1 [doi].
50. Schmidt M, Bohm D, von Törne C, Steiner E, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413. 68/13/5405 [pii];10.1158/0008-5472.CAN-07-5206 [doi].